METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.15547/tjs.2026.01.011Keywords:
hepatic steatosis, kidney damage, NAFLD, MASLD, CKD, metabolic syndromeAbstract
The nomenclature of non-alcoholic fatty liver disease (NAFLD) has recently undergone substantial revision to better reflect its underlying pathophysiological link with metabolic dysfunction. In 2023, the designation metabolic dysfunction-associated steatotic liver disease (MASLD) was formally adopted, superseding NAFLD. The updated definition incorporates the requirement for at least one cardiometabolic risk factor, thereby refining diagnostic accuracy and emphasizing the systemic nature of the condition.
Emerging evidence consistently demonstrates a strong association between MASLD and chronic kidney disease (CKD). This interrelation appears to be mediated through shared pathogenic mechanisms, including insulin resistance, chronic subclinical inflammation, endothelial dysfunction, and activation of the renin–angiotensin–aldosterone system. Notably, individuals with MASLD exhibit an elevated risk of developing CKD compared with those without metabolic hepatic steatosis, independent of conventional risk factors.
References
Wong, V.W., Ekstedt, M., Wong, G.L., Hagstrom, H., Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol, 79:842-852, 2023.
Karlsen, T.H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., et al., The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, 399:61-116, 2022.
Chen, T.K., Knicely, D.H., Grams, M.E., Chronic kidney disease diagnosis and management: a review. JAMA, 322:1294-1304, 2019.
Byrne, C.D., Targher, G., NAFLD as a driver of chronic kidney disease. J Hepatol, 72:785-801, 2020.
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J.M., et al., Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 71:156-162, 2022.
Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 55:434-438, 1980.
Bilson, J., Mantovani, A., Byrne, C.D., Targher, G., Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab, 50(1):101506, 2024.
Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., et al., A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 73:202-209, 2020.
Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., et al., A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 78:1966-1986, 2023.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 81:492-542, 2024.
Targher, G., Chonchol, M., Bertolini, L., Rodella, S., Zenari, L., Lippi, G., et al., Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol, 19:1564-1570, 2008.
Chang, Y., Ryu, S., Sung, E., Woo, H.Y., Oh, E., Cha, K., et al., Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism, 57:569-576, 2008.
Wei, S., Song, J., Xie, Y., Huang, J., Yang, J., Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. Diabetes Res Clin Pract, 197:110563, 2023.
Liang, Y., Chen, H., Liu, Y., Hou, X., Wei, L., Bao, Y., et al., Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab, 107:88-97, 2022.
Kwon, S.Y., Park, J., Park, S.H., Lee, Y.B., Kim, G., Hur, K.Y., et al., MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep, 13:1796, 2023.
Chen, S., Pang, J., Huang, R., Xue, H., Chen, X., Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int, 17:595-605, 2023.
Noels, H., Lehrke, M., Vanholder, R., Jankowski, J., Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol, 17:528-542, 2021.
Charlton, A., Garzarella, J., Jandeleit-Dahm, K.A.M., Jha, J.C., Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology (Basel), 10:18, 2020.
Yang, M., Luo, S., Yang, J., Chen, W., He, L., Liu, D., et al., Crosstalk between the liver and kidney in diabetic nephropathy. Eur J Pharmacol, 931:175219, 2022.
Mitrofanova, A., Merscher, S., Fornoni, A., Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol, 19:629-645, 2023.
Hammoud, S.H., AlZaim, I., Al-Dhaheri, Y., Eid, A.H., El-Yazbi, A.F., Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases. Front Endocrinol (Lausanne), 12:707126, 2021.
D’Marco, L., Salazar, J., Cortez, M., Salazar, M., Wettel, M., Lima-Martínez, M., et al., Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease. Kidney Res Clin Pract, 38:365-372, 2019.
Qi, X.Y., Qu, S.L., Xiong, W.H., Rom, O., Chang, L., Jiang, Z.S., Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. Cardiovasc Diabetol, 17:134, 2018.
Arabi, T., Shafqat, A., Sabbah, B.N., Fawzy, N.A., Shah, H., Abdulkader, H., et al., Obesity-related kidney disease: beyond hypertension and insulin-resistance. Front Endocrinol (Lausanne), 13:1095211, 2022.
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., et al., PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets. Pharmacol Ther, 245:108391, 2023.
Ma, Y., Shi, M., Wang, Y., Liu, J., PPARγ and its agonists in chronic kidney disease. Int J Nephrol, 2020:2917474, 2020.
Krukowski, H., Valkenburg, S., Madella, A.M., Garssen, J., vanBergenhenegouwen, J., Overbeek, S.A., et al., Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential. Nat Rev Nephrol, 19:87-101, 2023.
Bilson, J., Sethi, J.K., Byrne, C.D., Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. Proc Nutr Soc, 81:146-161, 2022.
Beker, B.M., Colombo, I., Gonzalez-Torres, H., Musso, C.G., Decreasing microbiota-derived uremic toxins to improve CKD outcomes. Clin Kidney J, 15:2214-2229, 2022.
Salguero, M.V., Al-Obaide, M.A.I., Singh, R., Siepmann, T., Vasylyeva, T.L., Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med, 18:3461-3469, 2019.
Magliocca, G., Mone, P., Di Iorio, B.R., Heidland, A., Marzocco, S., Short-chain fatty acids in chronic kidney disease: focus on inflammation and oxidative stress regulation. Int J Mol Sci, 23:5354, 2022.
Stavropoulou, E., Kantartzi, K., Tsigalou, C., Konstantinidis, T., Romanidou, G., Voidarou, C., et al., Focus on the gut-kidney axis in health and disease. Front Med (Lausanne), 7:620102, 2020.
Wang, T.Y., Wang, R.F., Bu, Z.Y., Targher, G., Byrne, C.D., Sun, D.Q., et al., Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol, 18:259-268, 2022.
Mantovani, A., Zusi, C., PNPLA3 gene and kidney disease. Explor Med, 1:42-50, 2020.
Mantovani, A., Taliento, A., Zusi, C., Baselli, G., Prati, D., Granata, S., et al., PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings. Liver Int, 40:1130-1141, 2020.
Mantovani, A., Pelusi, S., Margarita, S., Malvestiti, F., Dell'Alma, M., Bianco, C., et al., Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction. Aliment Pharmacol Ther, 57:1093-1102, 2023.
Kidney Disease: Improving Global Outcomes (KDIGO), KDIGO 2022 Clinical Practice Guideline for CKD management. Kidney Int, 102(Suppl 1):S1-S157, 2022.
Armstrong, M.J., et al., Weight loss and histological outcomes in NAFLD/MASH. Hepatology, 78(4):997-1008, 2023.
Harrison, S.A., et al., Resmetirom in MASH: the MAESTRO-NASH trial. N Engl J Med, 390(5):497-509, 2024.
Madrigal Pharmaceuticals, MAESTRO-NASH top-line results. Company report, 2024
Patton, H., et al., Semaglutide for NASH resolution: ESSENCE study. Lancet Gastroenterol Hepatol, 10(1):12-22, 2025.
Perkovic, V., et al., Semaglutide reduces CKD progression: FLOW trial. N Engl J Med, 391(2):109-121, 2024.
American Diabetes Association (ADA) News, Semaglutide reduces kidney events and mortality in FLOW. Press release, 2025.
Zheng, S.L., et al., Effects of SGLT2 inhibitors on liver and kidney: a meta-analysis. Diabetes Care, 46(9):1950-1962, 2023.
Cusi, K., et al., Pioglitazone for biopsy-proven NASH: a long-term safety and efficacy analysis. Diabetes, 72(7):1239-1249, 2023.
Lavine, J.E., et al., Vitamin E in non-diabetic NASH: randomized trial. JAMA, 327(16):1550-1559, 2022.
Ratziu, V., et al., Lanifibranor in MASH: phase IIb results. Hepatology, 78(5):1826-1837, 2023.
Alkhouri, N., et al., FXR agonists and HSD17B13 RNAi therapies for NASH. Gastroenterology, 166(3):745-760, 2024.
Levey, A.S., et al., Metformin safety in CKD: updates from KDIGO 2022. Clin J Am Soc Nephrol, 17(5):712-723, 2022.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
